The embodiments provide a calcitonin gene-related peptide (CGRP) agonist peptide or pharmaceutically acceptable salt thereof, including pharmaceutical compositions comprising a CGRP agonist peptide. The embodiments further provide treatment methods, including method of treating metabolic disorders and metabolic disorders selected from metabolic syndrome, diabetes and obesity. The methods involve administering to a subject in need thereof an effective amount of CGRP peptide.
